CLRB a massive dilution here. I don't trust this company. Security Notes
Capital Change=shs increased by 4 for 1 split Ex-date=06/13/2005. Rec date=05/25/2005. Pay date=06/10/2005.
Capital Change=shs decreased by 1 for 153 split Pay date=04/11/2011.
Capital Change=shs decreased by 1 for 20 split Ex-date=06/16/2014.
Capital Change=shs decreased by 1 for 10 split. Ex-date=03/07/2016.
1 to 153 ,wow.
not surprised by current price. the $25m offering say it all.
Key Risks and Uncertainties We are subject to numerous risks and uncertainties, including the following: • We will require additional capital in order to continue our operations, and may have difficulty raising additional capital; • We are a clinical-stage company with a going concern qualification to our financial statements and a history of losses, and we can provide no assurance as to our future operating results; • We have a history of recurring losses and an accumulated deficit, which, among other factors, raise substantial doubt about our ability to continue as a going concern, which in turn may hinder our ability to obtain future financing; • We have had significant management turnover in the last year, we continue to depend on key personnel who may terminate their employment with us at any time and our success will depend on our ability to hire additional qualified personnel; • At present, our success depends solely on the successful development and commercialization of our compounds in development, which cannot be assured; • The failure to complete development of our technology, to obtain government approvals, including required FDA approvals, or to comply with ongoing governmental regulations could prevent, delay or limit the introduction or sale of proposed products and result in failure to achieve revenues or maintain our ongoing business; • Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; • We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidates; • We have limited in-house research and manufacturing capacity and will continue to rely, to some extent, on research and manufacturing facilities at various universities, hospitals, contract research organizations and contract manufacturers for a portion of our research, development and manufacturing. In the event we exceed our in-house capacity or lose access to those facilities, our ability to gain FDA approval and commercialization of our drug delivery technology and products could be delayed or impaired;
5
• We expect to rely heavily on orphan drug status to develop and commercialize our product candidates, but our orphan drug designations may not confer marketing exclusivity or other expected benefits; • We are exposed to product, clinical and pre-clinical liability risks that could create a substantial financial burden should we be sued; • Acceptance of our products in the marketplace is uncertain and failure to achieve market acceptance will prevent or delay our ability to generate revenues; • We may face litigation from third parties who claim that our products infringe on their intellectual property rights, particularly because there is often substantial uncertainty about the validity and breadth of medical patents; • If we are unable to protect or enforce our rights to intellectual property adequately or to secure rights to third-party patents, we may lose valuable rights, experience reduced market share, assuming any, or incur costly litigation to protect our intellectual property rights; • Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete; • We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers; • The use of hazardous materials, including radioactive materials, in our research and development imposes certain compliance costs on us and may subject us to liability for claims arising from the use or misuse of these materials; • Due to our limited marketing, sales and distribution experience, we may be unsuccessful in our efforts to sell our proposed products, enter into relationships with third parties or develop a direct sales organization; • If we are unable to convince physicians of the benefits of our intended products, we may incur delays or additional expense in our attempt to establish market acceptance; • The market for our proposed products is rapidly changing and competitive, and new therapeutics, new drugs and new treatments that may be developed by others could impair our ability to maintain and grow our business and remain competitive; • If users of our products are unable to obtain adequate reimbursement from third-party payers, or if additional healthcare reform measures are adopted, it could hinder or prevent our product candidates’ commercial success; • Our stock price has experienced price fluctuations; • Four of our stockholders own in the aggregate approximately 26% of our outstanding common stock, which limits the influence of other stockholders; • If we fail to maintain effective internal controls over financial reporting, the price of our common stock may be adversely affected; • We are required to comply with certain provisions of Section 404 of the Sarbanes-Oxley Act of 2002 and if we fail to continue to comply, our business could be harmed and our stock price could decline; • Our common stock could be further diluted as the result of the issuance of additional shares of common stock, convertible securities, warrants or options; • Provisions of our charter, bylaws, and Delaware law may make an acquisition of us or a change in our management more difficult; and • We have not paid dividends in the past and do not expect to pay dividends for the foreseeable future. Any return on investment may be limited to the value of our common stock. For more information regarding the material risks and uncertainties we face, please see “Risk Factors” beginning on page [?] of this prospectus.
AI
Market Data 
Markets 
